Article Versions Notes

Karmokar A, Sargeant R, Hughes AM, Baakza H, Wilson Z, Talbot S, Bloomfield S, Leo E, Jones GN, Likhatcheva M, et al. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models. Cancers. 2023; 15(16):4195. https://doi.org/10.3390/cancers15164195

Karmokar, Ankur, Rebecca Sargeant, Adina M. Hughes, Hana Baakza, Zena Wilson, Sara Talbot, Sarah Bloomfield, Elisabetta Leo, Gemma N. Jones, Maria Likhatcheva, and et al. 2023. "Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models" Cancers 15, no. 16: 4195. https://doi.org/10.3390/cancers15164195

Karmokar, A., Sargeant, R., Hughes, A. M., Baakza, H., Wilson, Z., Talbot, S., Bloomfield, S., Leo, E., Jones, G. N., Likhatcheva, M., Tobalina, L., Dean, E., Cadogan, E. B., & Lau, A. (2023). Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models. Cancers, 15(16), 4195. https://doi.org/10.3390/cancers15164195